HAEMACURE ANNOUNCES WEBCAST OF PRESENTATION AT
ACUMEN BIOFIN RODMAN & RENSHAW 4TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Montreal, Quebec, May 9, 2007 - Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company developing high-value human proteins, today announced the webcast of its presentation at Acumen BioFin Rodman & Renshaw’s 4th Annual Global Healthcare Conference on Tuesday, May 15, 2007 in the Zephyr Salon Room at The Le Méridien Beach Plaza Hotel in Monte Carlo, Monaco, beginning at 2:15 p.m Central European Summer Time (8:15 a.m. U.S. Eastern Daylight Time).
Rodman & Renshaw will webcast the audio portion of the presentation and post the associated slides via its website at www.rodmanandrenshaw.com, hosted by Wall Street Webcasting. To access the live broadcast via internet in listen-only mode, or the subsequently archived recording, please cut and paste the following link directly into your web browser:
http://www.wsw.com/webcast/rrshq11/hae.cn
Please visit the site at least five minutes prior to start time for instructions.
About Acumen BioFin Rodman & Renshaw’s Annual Global Healthcare Conference
The Conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. The Conference will be attended by investors, venture capitalists, company executives, scientists and other industry leaders. Since 1951, Rodman & Renshaw has been dedicated to serving the needs of companies in emerging growth sectors and the investors that seek value in these companies. The Acumen BioFin division of Rodman & Renshaw is exclusively focused on healthcare and life science companies. For further information, visit www.rodmanandrenshaw.com.
About Haemacure
Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure’s research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats.
Hemaseel™HMN, Haemacure’s lead product candidate, is a human-derived fibrin sealant in late-stage clinical development. Haemacure’s second product candidate is human thrombin, a component of its fibrin sealant. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical hemostats, biomaterial combinations and drug delivery in select therapeutic areas. Haemacure has recently discovered additional specialty proteins in its plasma-derived intermediates and will advance these specialty proteins through partnerships with other pharmaceutical and biotechnology companies.
Forward-looking Statements
Certain statements contained in this news release and oral statements made by representatives of Haemacure that are not historical facts may be considered forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, the ability of Haemacure to set up its planned manufacturing facility, the completion and outcome of clinical studies as well as the development of new products, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure Corporation disclaims any intention or obligation to update these statements.
For more information :
Haemacure Corporation
Gilles Lemieux
Secretary
(514) 282-3350 ext. 22
glemieux@haemacure.ca
LaVoie Group
Martin A. Reynolds
Investor Relations
(978) 745-4200 ext. 107
mreynolds@lavoiegroup.com
